Literature DB >> 15133823

Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.

W Farid Abdo1, Daniëlle De Jong, Jan C M Hendriks, Martin W I M Horstink, Berry P H Kremer, Bastiaan R Bloem, Marcel M Verbeek.   

Abstract

We investigated whether cerebrospinal fluid (CSF) analysis discriminates between idiopathic Parkinson's disease (PD; n = 35) and multiple system atrophy (MSA; n = 30). The median CSF concentration of the neurotransmitter metabolites 5-hydroxyindolacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) was reduced significantly (49-70%) in MSA compared to PD. In contrast, several brain-specific proteins (tau, neuron-specific enolase, myelin basic protein) were elevated (130-230%) in MSA compared with those in PD. A combination of CSF tau and MHPG discriminated PD from MSA (adjusted odds ratios: tau, 27.2; MHPG, 0.14). Our data suggest that the more progressive and widespread neurodegenerative nature of MSA, as compared with PD, is reflected in the composition of CSF. We propose that CSF analysis may become part of the diagnostic work-up of patients with parkinsonian syndromes. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133823     DOI: 10.1002/mds.10714

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease).

Authors:  Graham W Kay; Marcel M Verbeek; Julie M Furlong; Michèl A A P Willemsen; David N Palmer
Journal:  Neurochem Int       Date:  2009-08-05       Impact factor: 3.921

3.  CSF neurofilament protein analysis in the differential diagnosis of ALS.

Authors:  Thierry S Reijn; Wilson F Abdo; Helenius J Schelhaas; Marcel M Verbeek
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

4.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

5.  Striatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B.

Authors:  Cristiane Batassini; Núbia Broetto; Lucas Silva Tortorelli; Milene Borsoi; Caroline Zanotto; Fabiana Galland; Tadeu Mello Souza; Marina Concli Leite; Carlos-Alberto Gonçalves
Journal:  Neural Plast       Date:  2015-05-18       Impact factor: 3.599

6.  Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart.

Authors:  Enrica Olivola; Mariangela Pierantozzi; Paola Imbriani; Claudio Liguori; Mario Stampanoni Bassi; Marco Conti; Vincenza D'Angelo; Nicola Biagio Mercuri; Alessandro Stefani
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

Review 7.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

Review 8.  Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.

Authors:  Dan Xie; Ling Feng; Hongyan Huang; Quanzhen Zhao; Pingping Ning; Qiuyan Shen; Haitao Lu; Fang Xu; Yanming Xu
Journal:  Behav Neurol       Date:  2021-05-31       Impact factor: 3.342

9.  Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.

Authors:  Anouke van Rumund; Marjolein B Aerts; Rianne A J Esselink; Frederick J A Meijer; Marcel M Verbeek; Bastiaan R Bloem
Journal:  BMC Neurol       Date:  2018-05-16       Impact factor: 2.474

10.  Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

Authors:  Chin-Hsien Lin; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Jen-Jie Chieh; Hsin-Hsien Chen; Bing-Hsien Liu; Ming-Jang Chiu
Journal:  Front Aging Neurosci       Date:  2018-04-27       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.